Overview

Prevention and Treatment of Nausea Associated With Motion Sickness in Senior Subjects

Status:
Recruiting
Trial end date:
2020-02-01
Target enrollment:
Participant gender:
Summary
A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of the Safety, Efficacy and Pharmacokinetics of DPI 386 Nasal Gel for the Prevention and Treatment of Nausea Associated with Motion Sickness in Senior Subjects With Open-Label Follow-Up
Phase:
Phase 3
Details
Lead Sponsor:
Repurposed Therapeutics, Inc.
Treatments:
Butylscopolammonium Bromide
Scopolamine